Quincy Medical Group offering new, innovative treatment option for nasal airway obstruction

QUINCY — Quincy Medical Group now offers VivAer, a minimally-invasive FDA-cleared technology that provides lasting relief from chronic nasal airway obstruction.

Dr. Paul Conrad and Dr. Abraham Sheffield, ear, nose and throat physicians at QMG, offer this new treatment option for patients. Nasal airway obstruction is a common but often undiagnosed condition. More than 20 million Americans suffer from nasal obstruction in the United States.

Nasal obstruction is often caused by anatomical blockage in the nose, hindering airflow. As a result, patients may feel congested or “stuffy.” Common symptoms include nasal congestion or stuffiness, trouble breathing through the nose, trouble sleeping and difficulty breathing well during exercise or exertion. For many patients, management of this condition with medications and sprays is inadequate or offers only temporary relief.

“If you regularly experience difficulty breathing through your nose, especially at night, and nothing seems to help but decongestants or Breathe Rights, you likely have enlarged nasal turbinates and/or nasal valve collapse,” Dr. Conrad said in a press release. “Until recently, finding a long-term solution for these problems often meant surgery. Now, with VivAer, we’re able to offer an in-office, convenient and minimally-invasive procedure that gradually opens your nasal airway to help you breathe better.”

VivAer features a thin, wand-like, temperature-controlled stylus that attaches to a console. The stylus is inserted via the nostril to gently remodel the nasal tissue and improve air flow using patented temperature-controlled radiofrequency technology that delivers precise therapeutic benefits. Treatment with VivAer can be performed with a local anesthetic during a routine office visit, with no incisions, minimal to no downtime and minimal discomfort. Patients typically return to normal activity on the same day.